Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow. Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.
Tamsulosin was first approved by the FDA on April 15, 1997.
Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.
Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.
Hadassah Medical Organization, Jerusalem, Israel
Pfizer Investigational Site, Bristol, United Kingdom
Urology department, Soroka university medical center, Beer-Sheva, p,o,box 151, Israel
William Beaumont Hospital, Royal Oak, Michigan, United States
The George Washington University Medical Center, Washington, District of Columbia, United States
University of Alabama - Birmingham, Birmingham, Alabama, United States
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, United Kingdom
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.